stockrowNeoGenomics, Inc.
NEO Healthcare Diagnostics & Research
NeoGenomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $727.3 million, up 10.1% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- +72.1%
- Free cash flow
- −3,724.2%
- Total debt
- +10.9%
Quarter to September 2026, against a year earlier
Follow NEO
Alert me
NeoGenomics, Inc. (NEO) EBITDA
NeoGenomics, Inc.'s EBITDA for fiscal 2025 was −$46.1M, compared with −$16.6M in fiscal 2024. Over the twelve months to 30 September 2026 it was $17.5M. Over the past ten years it has ranged from −$85.4M (fiscal 2022) to $43.7M (fiscal 2019); the current reading is higher than 27% of that period. NeoGenomics, Inc. ranks 21st of 49 Diagnostics & Research companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$46.1M | — |
| FY2024 | −$16.6M | — |
| FY2023 | −$32.3M | — |
| FY2022 | −$85.4M | — |
| FY2021 | −$62.7M | — |
| FY2020 | $26.3M | (39.88%) |
| FY2019 | $43.7M | 35.13% |
| FY2018 | $32.3M | 24.61% |
| FY2017 | $25.9M | (10.15%) |
| FY2016 | $28.9M | 1,815.13% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $8.8M | 21.42% |
| Jun 2026 | $7.2M | — |
| Mar 2026 | −$1.8M | — |
| Dec 2025 | $3.4M | — |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| CDNA CareDx, Inc. compare | $141.4M |
| VCYT Veracyte, Inc. compare | $123.9M |
| NEO NeoGenomics, Inc. | $17.5M |
| FRNM Freenome, Inc compare | −$4.3M |
| CSTL Castle Biosciences, Inc. compare | −$14.0M |
| ADPT Adaptive Biotechnologies Corporation compare | −$22.4M |
| OPK OPKO Health, Inc. compare | −$37.5M |
| WGS GeneDx Holdings Corp. compare | −$65.5M |
| PSNL Personalis, Inc. compare | −$108.6M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on NEO
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement